Trial reportEuropean journal of nuclear medicine and molecular imaging2018
Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study.
Trial report in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of imaging in the management of progressive glioblastoma in adults.Journal of neuro-oncology · 2022Pooled it
- Cerenkov luminescence microscopy: A novel approach for high-resolution radiotracer imaging.iScience · 2025Article
- Article
- The relationship between gadolinium enhancement and [18 F]fluorothymidine uptake in brain lesions with the use of hybrid PET/MRI.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group.The Lancet. Oncology · 2024Review
- Diagnostic value of PET with different radiotracers and MRI for recurrent glioma: a Bayesian network meta-analysis.BMJ open · 2023Review
- Investigational PET tracers in neuro-oncology-What's on the horizon? A report of the PET/RANO group.Neuro-oncology · 2022Article
- Radiomics for pseudoprogression prediction in high grade gliomas: added value of MR contrast agent.Heliyon · 2022Article
- Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma.NMR in biomedicine · 2022Review
- Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI,Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Article
- Physiological Imaging Methods for Evaluating Response to Immunotherapies in Glioblastomas.International journal of molecular sciences · 2021Review
- Imaging for Response Assessment in Cancer Clinical Trials.Seminars in nuclear medicine · 2020Article
- Recent advances of PET imaging in clinical radiation oncology.Radiation oncology (London, England) · 2020Review
- Article
- Preclinical Evaluation of Radiolabeled Peptides for PET Imaging of Glioblastoma Multiforme.Molecules (Basel, Switzerland) · 2019Article
- Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas.Contrast media & molecular imaging · 2018Review
- Magnetic resonance spectroscopy outperforms perfusion in distinguishing between pseudoprogression and disease progression in patients with glioblastoma.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeResponse evaluation in patients with glioblastoma after chemoradiotherapy is challenging due to progressive, contrast-enhancing lesions on MRI that do not reflect true tumour progression. In this study, we prospectively evaluated the ability of the PET tracer
methodsFLT PET and MRI scans were performed before and 4 weeks after chemoradiotherapy. MRI scans were also performed after three cycles of adjuvant temozolomide. Pseudoprogression was defined as progressive disease on MRI after chemoradiotherapy with stabilisation or reduction of contrast-enhanced lesions after three cycles of temozolomide, and was compared with the disease course during long-term follow-up. Changes in maximum standardized uptake value (SUV
resultsBetween 2009 and 2012, 30 patients were included. Of 24 evaluable patients, 7 showed pseudoprogression and 7 had true progression as defined by MRI response. FLT PET parameters did not significantly differ between patients with true progression and pseudoprogression defined by MRI. The correlation between change in SUV
conclusionBaseline FLT uptake appears to be predictive of overall survival. Furthermore, changes in SUV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.